Application of epitope enhancement to a prophylactic DNA vaccine for hepatitis C virus (HCV) in an HLA-A2.1 transgenic mouse model: Enhanced HCV specific CTL induction and protection from HCV-recombinant vaccinia infection.

被引：0

作者：

Arichi, T

Major, ME

Saito, T

Nishioka, M

Engelhard, VH

Feinstone, SM

Berzolsky, JA

机构：

[1] Kagawa Med Univ, Kagawa, Japan

[2] US FDA, Bethesda, MD 20014 USA

[3] Yamagata Univ, Sch Med, Yamagata 99023, Japan

[4] Univ Virginia, Charlottesville, VA 22903 USA

[5] NCI, NIH, Bethesda, MD 20892 USA

来源：

HEPATOLOGY | 2000年 / 32卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

853

引用

页码：373A / 373A

页数：1

共 8 条

[1] A DNA vaccine as a prophylaxis for hepatitis C virus (HCV) infection. HCV specific CTL induction and protection from HCV-recombinant vaccinia infection in an HLA-A2.1 transgenic mouse model.
Arichi, T
Saito, T
Major, ME
Shirai, M
Engelhard, VH
Feinstone, SM
Berzofsky, JA
[J]. HEPATOLOGY, 1999, 30 (04) : 409A - 409A
[2] Dna vaccine for prophylaxis of hepatitis C virus (HCV) infection: Induction of HCV specific CTLs and protection from HCV-recombinant vaccinia infection in HLA-A2.1 transgenic mouse model.
Arichi, T
Saito, T
Major, ME
Shirai, M
Feinstone, SM
Berzofsky, JA
[J]. FASEB JOURNAL, 1999, 13 (04): : A634 - A634
[3] Prophylactic DNA vaccine for hepatitis C virus (HCV) infection: HCV-specific cytotoxic T lymphocyte induction and protection from HCV-recombinant vaccinia infection in an HLA-A2.1 transgenic mouse model, (Retraction of vol 97, pg 297, 2000)
Arichi, T
Saito, T
Major, ME
Belyakov, IM
Shirai, M
Engelhard, VH
Feinstone, SM
Berzofsky, JA
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (10) : 5943 - 5943
[4] RETRACTED: Prophylactic DNA vaccine for hepatitis C virus (HCV) infection: HCV-specific cytotoxic T lymphocyte induction and protection from HCV-recombinant vaccinia infection in an HLA-A2.1 transgenic mouse model (Retracted Article. See vol 98, pg 5943, 2001)
Arichi, T
Saito, T
Major, ME
Belyakov, IM
Shirai, M
Engelhard, VH
Feinstone, SM
Berzofsky, JA
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (01) : 297 - 302
[5] DNA immunization with hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming-recombinant canarypox virus boosting induces immune responses and protection from recombinant HCV-vaccinia virus infection in HLA-A2.1-transgenic mice
Pancholi, P
Perkus, M
Tricoche, N
Liu, QY
Prince, AM
[J]. JOURNAL OF VIROLOGY, 2003, 77 (01) : 382 - 390
[6] Protection against infection with an HCV-recombinant vaccinia virus by vaccination with an adenoviral vector enconding hepatitis C virus (HCV) NS4a protein
Arribillaga, L
Sarobe, P
Gorraiz, M
Bruna-Romero, O
Borras-Cuesta, F
Prieto, J
Ruiz, J
Lasarte, JJ
[J]. JOURNAL OF HEPATOLOGY, 2004, 40 : 115 - 116
[7] Immunization with hepatitis C virus-like particles induces protection from HCV-recombinant vaccinia infection in mice.
Lechmann, MT
Vergalla, J
Satoi, J
Triyatni, M
Baumert, TF
Liang, JT
[J]. HEPATOLOGY, 2000, 32 (04) : 268A - 268A
[8] A liposomal peptide vaccine inducing CD8+ T cells in HLA-A2.1 transgenic mice, which recognise human cells encoding hepatitis C virus (HCV) proteins
Engler, OB
Schwendener, RA
Dai, WJ
Wölk, B
Pichler, W
Moradpour, D
Brunner, T
Cerny, A
[J]. VACCINE, 2004, 23 (01) : 58 - 68

← 1 →